Doctors currently prescribe semaglutide and tirzepatide mainly to treat obesity and type 2 diabetes, but researchers are discovering that these medicines may have effects far beyond weight loss and blood sugar control.
One surprising possibility is that they may reduce alcohol consumption in people with alcohol use disorder. A large new study published in BMJ Open has added important evidence supporting this idea.
Alcohol use disorder affects millions of people worldwide and can damage almost every organ in the body. Heavy drinking increases the risk of liver disease, cancer, heart disease, accidents, depression, and early death. Despite available treatments, many people continue to relapse or require repeated hospital care.
The research team analysed medical records from more than 40,000 adults diagnosed with alcohol use disorder who also had obesity or type 2 diabetes. They compared people starting semaglutide or tirzepatide with patients taking alternative medicines for diabetes, obesity, or alcohol dependence.
Across four separate study groups, people receiving GLP-1 receptor agonists consistently experienced fewer hospital admissions related to alcohol. The reductions ranged from 26% to 32% when compared with standard diabetes or obesity medicines and exceeded 60% when compared with medicines commonly prescribed for alcohol use disorder.
Scientists are still trying to understand why these medicines may influence drinking behaviour. Previous studies suggest GLP-1 drugs may affect reward pathways in the brain that influence cravings and addictive behaviours. If this is correct, the medicines could help reduce the desire to drink alcohol as well as improve physical health.
However, the study has important limitations. Because it relied on existing health records, researchers could not measure exactly how much alcohol each participant drank. Alcohol use disorder is also frequently underreported, meaning some patients may not have been identified.
The authors also pointed out that people who receive newer GLP-1 medicines may differ from other patients in ways that are difficult to measure. These medicines are relatively expensive, so people with better healthcare access or different health characteristics may have been more likely to receive them. These factors could partly explain the observed benefits.
Another limitation was that many participants stopped taking their medicine before the study ended. This makes it harder to estimate the true long-term effects. The strongest reductions were also seen in comparisons with alcohol use disorder medicines, where the possibility of hidden bias was greatest.
Even with these limitations, the findings are exciting because they were remarkably consistent across different patient groups. They suggest that GLP-1 receptor agonists deserve careful testing in future clinical trials designed specifically for alcohol use disorder.
Overall, this study does not prove that semaglutide or tirzepatide treat alcohol addiction, but it provides an important clue that they might. If future randomised trials confirm these results, doctors could eventually have a completely new way to reduce alcohol-related illness while also treating obesity or diabetes in many patients.
If you care about wellness, please read studies about how alcohol affects liver health and disease progression, and even one drink a day could still harm blood pressure health.
For more health information, please see studies that your age may decide whether alcohol is good or bad for you, and people over 40 need to prevent dangerous alcohol/drug interactions.
Source: BMJ Open.
